BD PROJECTS
Product for Licensing
If your company is interested in the new NMTi payload, please contact DrugTimes BD team as soon as possible!
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn
If interested in this asset, please contact DrugTimes BD Team at BD@drugtimes.cn. Many thanks!
无法提供摘要。这是一篇受保护的文章。
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn
If interested in this asset, please contact DrugTimes BD Team at BD@drugtimes.cn. Many thanks!
If you are interested in this product, please contact us at BD@drugtimes.cn. Many thanks!
If interested in this asset, please contact DrugTimes BD Team at BD@drugtimes.cn. Many thanks!
Request for Product
Please contact the DrugTimes BD team as soon as possible!
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn
If interested in this licensing opportunity, please contact DrugTimes BD Team at BD@drugtimes.cn
If your company is interested in this opportunity, please contact us as soon as possible!
If interested, please send an email message to BD@drugtimes.cn, and indicate the project ID in the subject line
If interested, please send an email message to BD@drugtimes.cn, and indicate the project ID in the subject line
If interested, please send an email message to BD@drugtimes.cn, and indicate the project ID in the subject line
Project ID: BP-20240430-L-EE-81 About IBD Inflammatory bowel disease (IBD) is a gro…
Please contact us. Our email address is BD@drugtimes.cn
Bio News
Congratulations to Lilly and Morphic! This acquisition will expand Lilly’s immunology pipeline with oral integrin therapies
This is an important milestone for China’s innovative drug industry.
Congratulations to Eli Lilly and AD patients!
Warmest congratulations to Eli Lilly and Radionetics Oncology!
Warmest congratulations to Merck and Orion, and to prostate cancer patients!
Congratulations to Alnylam and patients who may benefit from this exciting progress!
Congratulations to Novo Nordisk and diabetes patients!
Congratulations to Gilead Sciences and HIV patients!
Congratulations to Sarepta Therapeutics and DMD patients!
Congratulations to Day One Biopharmaceuticals!
Congratulations to Day One Biopharmaceuticals and MabCare Therapeutics!
Congratulations to Roche and Ascidian Therapeutics!
Insights
DrugTimes Team will follow up on this subject. Please stay tuned
Will J&J be the buyer? Please share your thoughts!~
DrugTimes will follow up on this subject. Please stay tuned
DrugTimes will present more reports. Please stay tuned
Roxadustat is a domestically produced Class 1 innovative drug originating from the United …
13 seasoned experts shared rather valuable information for 4 hours
DrugTimes will present more reports timely. Please stay tuned
All comments are highly welcome!
Where Pharma is Investing for the Future of Medicine: Biopharma Deal Making in 2024
DrugTimes team will follow up on this hot field and report timely. Please stay tuned. Many thanks!~
These presentations indicate that the era of domestically developed GLP-1 drugs for weight loss in China is on the horizon, with significant implications for the future of obesity treatment
Welcome friends to share your views in the comments section! DrugTimes will continue to pay close attention and follow up on the reports